AstraZeneca's clot-fighter Brilinta shows promise in diabetics with heart disease in big study

As Pascal Soriot polishes the rough edges of his R&D shop within AstraZeneca, the British drugmaker reported some encouraging news that could help it expand the use of its clot-fighter Brilinta, once touted as a $3.5 billion-a-year treatment.